Drug Type ASO |
Synonyms ALG021618 |
Target- |
Action inhibitors |
Mechanism Hepatitis B virus inhibitors, RNA interference |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |

| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Hepatitis B | Preclinical | United States | 22 Jun 2022 |





